<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04354025</url>
  </required_header>
  <id_info>
    <org_study_id>20-x130</org_study_id>
    <nct_id>NCT04354025</nct_id>
  </id_info>
  <brief_title>Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML</brief_title>
  <official_title>A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 clinical trial investigates the effectiveness of cytokine-induced memory-like&#xD;
      natural killer (CIML NK) cells in combination with FLAG chemotherapy as a treatment for&#xD;
      refractory or relapsed AML. Previous studies in adults with AML sowed successful induction of&#xD;
      remission and a previous phase 1 study demonstrated that CIML NK cells can be used safely in&#xD;
      pediatric patients. This phase 2 study uses FLAG chemotherapy to lower leukemic burden and&#xD;
      suppress the recipient's immune system to provide an optimal environment for CIML NK cell&#xD;
      expansion and anti-leukemic activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (complete remission (CR) plus complete remission with incomplete blood count recovery (CRi))</measure>
    <time_frame>Day 28</time_frame>
    <description>Complete remission (CR) requires all of the following:&#xD;
Bone marrow:&#xD;
Morphologically leukemia free state (≤ 5% myeloblasts) with normal maturation of all cell lines. Persistent dysplasia may be noted&#xD;
Peripheral blood:&#xD;
Platelets ≥ 100,000/uL&#xD;
Neutrophils ≥ 1000/uL&#xD;
Complete remission with incomplete blood count recovery (CRi):&#xD;
All of the above criteria for CR must be met, except that absolute neutrophils &lt;1000/μL or platelets &lt;100,000 /μL in the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients able to proceed to stem cell transplant</measure>
    <time_frame>Up to 60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>-DFS is defined as the time from the day CR or CRi is documented until disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>-OS is defined from the date of first dose of fludarabine on this study until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who achieve minimum residual disease (MRD)-negative status</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of regimen as measured by number of adverse events</measure>
    <time_frame>From Day 0 to Day 100</time_frame>
    <description>-Adverse events will be collected from Day 0 to Day 35; however, bone marrow suppression (ANC ≤ 500/mcL) and adverse events of GVHD involving the liver, skin, or gastrointestinal tract will be recorded to Day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Relapsed Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Recipient: FLAG + CIML NK Cells + IL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-The recipient will begin a chemotherapy regimen of fludarabine, cytarabine and GCSF starting on Day -7. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20 L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. CIML NK cells will be infused at maximum cell dose of 10 x 106/kg. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donor:</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>-On Day -1 (one day before the planned NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard apheresis over 4-5 hours (with a target volume of at least 20 L) from the identified haploidentical donor. The apheresis procedure will be done as per standard institutional procedures (which may include placement of a central line if necessary). If the goal minimum NK cell dose will not be met based on the initial assessment of the leukapheresis product, a second collection/procedure may be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cytokine induced memory-like NK cells</intervention_name>
    <description>-The CIML NK cells (maximum dose capped at 10 x 106/kg, minimum dose allowed is 0.5 x 106/kg) will be infused on Day 0 without a filter or pump.</description>
    <arm_group_label>Recipient: FLAG + CIML NK Cells + IL-2</arm_group_label>
    <other_name>CIML NK cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>-Fludarabine (dose: 30 mg/m^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.</description>
    <arm_group_label>Recipient: FLAG + CIML NK Cells + IL-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>-Ara-C (dose: 2000mg/m^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.</description>
    <arm_group_label>Recipient: FLAG + CIML NK Cells + IL-2</arm_group_label>
    <other_name>Cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>-Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.</description>
    <arm_group_label>Recipient: FLAG + CIML NK Cells + IL-2</arm_group_label>
    <other_name>Filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>-IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).</description>
    <arm_group_label>Recipient: FLAG + CIML NK Cells + IL-2</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>-Donor only</description>
    <arm_group_label>Donor:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Refractory AML without complete remission (CR) after induction therapy (primary&#xD;
             induction failure) or relapsed AML after obtaining a CR. Disease defined by one of the&#xD;
             following:&#xD;
&#xD;
             *≥ 5% blasts in the bone marrow (M2/M3 bone marrow), with or without extramedullary&#xD;
             disease&#xD;
&#xD;
             *absolute blast count greater than 1,000 per microliter in the peripheral blood with&#xD;
             or without extramedullary disease.&#xD;
&#xD;
          -  Age requirement for pediatric cohort: 1-21 years of age.&#xD;
&#xD;
          -  Available HLA-haploidentical donor that meets the following criteria:&#xD;
&#xD;
               -  Related donor (parent, sibling, offspring, or offspring of sibling)&#xD;
&#xD;
               -  At least 18 years of age&#xD;
&#xD;
               -  HLA-haploidentical donor/recipient match by at least Class I serologic typing at&#xD;
                  the A&amp;B locus.&#xD;
&#xD;
               -  In general, good health and medically able to tolerate leukapheresis required for&#xD;
                  harvesting the NK cells for this study.&#xD;
&#xD;
               -  Negative for hepatitis, HTLV, and HIV on donor viral screen&#xD;
&#xD;
               -  Not pregnant&#xD;
&#xD;
               -  Voluntary written consent to participate in this study&#xD;
&#xD;
          -  Patients with known CNS involvement with AML are eligible provided that they have been&#xD;
             treated and CSF is clear for at least 2 weeks prior to enrollment into the study. CNS&#xD;
             therapy (chemotherapy or radiation) should continue as medically indicated during the&#xD;
             study treatment.&#xD;
&#xD;
          -  Karnofsky/Lansky performance status &gt; 50 %&#xD;
&#xD;
          -  Adequate organ function as defined below:&#xD;
&#xD;
               -  Total bilirubin &lt; 2 mg/dL&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) &lt; 3.0 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Creatinine within normal institutional limits OR creatinine clearance &gt; 50&#xD;
                  mL/min/1.73 m2 by Schwartz formula or GFR (See Appendix B)&#xD;
&#xD;
               -  Oxygen saturation ≥90% on room air&#xD;
&#xD;
               -  Ejection fraction ≥35%&#xD;
&#xD;
          -  Able to be off corticosteroids and any other immune suppressive medications beginning&#xD;
             on Day -3 and continuing until 30 days after the infusion of the CIML NK cells.&#xD;
             However, use of low-level corticosteroids is permitted if deemed medically necessary.&#xD;
             Low-level corticosteroid use is defined as 10mg or less of prednisone (or equivalent&#xD;
             for other steroids) per day.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test within 28 days&#xD;
             prior to study registration. Female and male patients (along with their female&#xD;
             partners) must agree to use two forms of acceptable contraception, including one&#xD;
             barrier method, during participation in the study and throughout the DLT evaluation&#xD;
             period.&#xD;
&#xD;
          -  Ability to understand and willingness to sign an IRB approved written informed consent&#xD;
             document (or that of legally authorized representative, if applicable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relapsed after allogeneic transplantation.&#xD;
&#xD;
          -  Isolated extramedullary relapse&#xD;
&#xD;
          -  Circulating blast count &gt;30,000/µL by morphology or flow cytometry (cytoreductive&#xD;
             therapies including leukapheresis or hydroxyurea are allowed).&#xD;
&#xD;
          -  Patients with any of the following diagnoses:&#xD;
&#xD;
               -  Down's syndrome&#xD;
&#xD;
               -  Acute promyelocytic leukemia (APL)&#xD;
&#xD;
               -  Juvenile myelomonocytic leukemia (JMML)&#xD;
&#xD;
          -  Uncontrolled bacterial or viral infections, or known HIV, Hepatitis B or C infection.&#xD;
&#xD;
          -  Known hypersensitivity to one or more of the study agents.&#xD;
&#xD;
          -  Received any investigational drugs within the 14 days prior to the first dose of&#xD;
             fludarabine.&#xD;
&#xD;
          -  Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Bednarski, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Bednarski, M.D., Ph.D.</last_name>
    <phone>314-454-6018</phone>
    <email>bednarski_j@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeffrey Bednarski, M.D., Ph.D.</last_name>
      <phone>314-454-6018</phone>
      <email>bednarski_j@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Bednarski, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Cashen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Fehniger, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shalini Shenoy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Hayashi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sima Bhatt, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clare Zimmerman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John DiPersio, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Westervelt, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey Uy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravi Vij, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille Abboud, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meagan Jacoby, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iskra Pusic, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armin Ghobadi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Schroeder, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Stockerl-Goldstein, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristan Augustin, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feng Gao, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

